申请人:Nektar Therapeutics
公开号:US20200261587A1
公开(公告)日:2020-08-20
The invention relates to (among other things) polymer-sunitinib conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over sunitinib in unconjugated form.
该发明涉及聚合物-舒尼替尼共轭物和相关化合物。该发明的化合物在通过多种给药途径之一给予时,表现出比未共轭的舒尼替尼更具优势。